SHANGHAI--(BUSINESS WIRE)--Frontline BioVentures, a premier healthcare venture capital firm based in China, announced today that it has led a Series A round of financing for Sino Health, an invested company of Sinopharm.
Frontline BioVentures will provide Sino Health a rich pipeline of innovative products and cutting edge technologies through its network and portfolio companies while also providing seasoned investment expertise. Sinopharm will remain a key shareholder of Sino Health and continue to provide Sino Health with access to its distribution networks covering thousands of hospitals across China.
Frontline BioVentures will provide Sino Health a rich pipeline of innovative products and cutting edge technologies through its network and portfolio companies while also providing seasoned investment expertise. Sinopharm will remain a key shareholder of Sino Health and continue to provide Sino Health with access to its distribution networks covering thousands of hospitals across China.
